Skip to main content
BioInvent International logo

BioInvent International — Investor Relations & Filings

Ticker · BINV ISIN · SE0015244520 LEI · 549300E7QRHEF2IJUY10 ST Manufacturing
Open in API
Filings indexed 679 across all filing types
Latest filing 2023-04-27 AGM Information
Country SE Sweden
Listing ST BINV

About BioInvent International

https://www.bioinvent.com/en

BioInvent International is a clinical-stage company that discovers and develops novel, first-in-class immuno-modulatory antibodies for cancer therapy. Leveraging extensive expertise in immunology, cancer biology, and antibody biology, the company generates innovative immuno-oncology drug candidates for its clinical pipeline. BioInvent's operations include an in-house manufacturing facility to produce antibodies for its preclinical studies and clinical trials, with the goal of developing treatments that can transform the lives of cancer patients.

Recent filings

Filing Released Lang Actions
Beslut på BioInvents årsstämma 2023
AGM Information Classification · 98% confidence The document text is titled "Beslut på BioInvents årsstämma 2023" (Decisions at BioInvent's Annual General Meeting 2023). It details the outcomes of the Annual General Meeting (Årsstämma), including board elections, approval of remuneration reports, decisions on incentive programs (options), and authorization for future share issues. These are the core components of an AGM outcome announcement. Since the document explicitly reports the decisions made at the meeting rather than being a presentation (AGM-R) or a proxy solicitation document (DEF 14A/PSI), the most appropriate classification is AGM-R, which covers AGM materials and decisions. The document is a summary of the results, not a regulatory filing announcing the results (RPA/RNS), nor is it the full proxy statement.
2023-04-27 Swedish
Earnings Release 2023
Earnings Release Classification · 99% confidence The document is titled "DELÅRSRAPPORT Q1 2023" (Interim Report Q1 2023) and contains detailed financial summaries for the first quarter (Net sales, Net result, Cash flow, Liquid assets as of March 31, 2023). It also includes extensive operational updates on clinical trials (BI-1206, BI-1607, BI-1808, BT-001) and management commentary specific to the period. This structure—quarterly financial highlights combined with operational progress—is characteristic of an Interim Report, which corresponds to the 'IR' (Interim / Quarterly Report) filing type. It is comprehensive enough to be an IR, not just a brief ER (Earnings Release). Q1 2023
2023-04-26 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 100% confidence The document is titled 'UNLEASHING IMMUNITY TO FIGHT CANCER INTERIM REPORT Q1, 2023'. It contains substantive financial data, including net sales, profit/loss after tax, cash flow, and liquid funds for the first quarter of 2023. It also provides detailed operational updates, pipeline status, and clinical trial results. As it is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial statements and analysis, it is classified as an Interim/Quarterly Report. Q1 2023
2023-04-26 English
BioInvent announces a fourth complete response in Phase 1/2 trial with BI-1206 in non-Hodgkin’s lymphoma
Earnings Release Classification · 95% confidence The document is a press release dated April 20, 2023, announcing clinical trial updates (Phase 1/2 trial results for BI-1206 in NHL) and a new patent grant. It contains key financial/operational highlights but is not a comprehensive annual report (10-K) or a detailed interim report (IR). It is an initial announcement of results, fitting the definition of an Earnings Release (ER) which covers periodical financial/operational results highlights. Although it discusses clinical progress rather than pure financials, in the context of a biotech company, this type of announcement serves the function of an ER. The document concludes with a statement about information being submitted for publication pursuant to the EU Market Abuse Regulation, which is typical for regulatory news releases. Given the content focuses on trial progress and patent news, it is best classified as an Earnings Release (ER) as it announces key operational performance indicators, or potentially a Regulatory Filing (RNS) if ER is too focused on pure financials. Since it announces specific, time-sensitive operational achievements (trial responses, patent grant), ER is a strong fit, though RNS is a possible fallback. I will select ER as it is a specific announcement of performance updates. FY 2023
2023-04-20 English
En fjärde fullständig respons i BioInvents fas 1/2-studie med BI-1206 i non-Hodgkins lymfom
Regulatory Filings Classification · 94% confidence The document is a press release dated April 20, 2023, from BioInvent International AB, announcing clinical trial results (fourth complete response in a Phase 1/2 study for BI-1206) and a new patent grant in Japan. It contains key financial/operational updates but is not a comprehensive annual report (10-K) or a detailed interim report (IR). It is an initial announcement of results, which aligns best with an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it details specific operational and clinical progress rather than just financial highlights, and it is a formal announcement of material information, it fits the pattern of an Earnings Release (ER) which often includes operational updates alongside results, or a Regulatory Filing (RNS) if it's a general market disclosure. Given the focus on clinical trial progress and patent news, it is a significant corporate update. However, the structure strongly resembles a standard press release announcing key operational milestones and results, which is often categorized as an Earnings Release (ER) in financial databases, even if the results are clinical rather than purely quarterly financials. Since it is a formal announcement of material information, ER is a strong candidate, but RNS is the safest fallback for non-standard regulatory announcements. Given the content is a direct update on clinical progress and patent news, and it is not explicitly an earnings report, I will classify it as a Regulatory Filing (RNS) as it is a general regulatory announcement of material information not covered by other specific codes like DIV, CAP, or ER (which usually implies quarterly financials). The document length (5703 chars) is substantial enough to not be a simple RPA.
2023-04-20 Swedish
Annual Report (ESEF) 2022
Annual Report (ESEF) Classification · 100% confidence FY 2022
2023-04-06 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.